Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim about Vyvanse’s boxed warning content (high abuse/misuse potential leading to substance use disorder/addiction and increased overdose/death risk, including with higher doses and unapproved methods such as snorting or injection) is directly supported by the supplied FDA label excerpts (Boxed Warning and Warnings/Precautions and Drug Abuse/Dependence).
Category Scores
Accurate Statements
VYVANSE has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction.
Supported by BOX (Abuse, Misuse, and Addiction) and also reiterated in Warnings and Precautions (5.1) and Drug Abuse and Dependence (9.2).
Misuse and abuse of CNS stimulants, including VYVANSE, can result in overdose and death.
Supported by BOX and Warnings and Precautions (5.1), and consistent with Drug Abuse and Dependence (9.2) excerpt provided.
The risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Supported by BOX (and consistent with 5.1 and 9.2 excerpts provided), explicitly naming higher doses and unapproved methods including snorting or injection.
Unsupported Statements
Contradictions
Important Omissions
No prescriber-facing mitigation elements from the boxed warning (e.g., assess each patient's risk before prescribing, educate patients/families, proper storage/disposal, and frequently monitor for signs/symptoms) were included alongside the abuse/misuse risk statement.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is consistent with the label’s abuse/misuse boxed warning and does not introduce dosing, contraindication, or interaction instructions beyond what the label excerpt supports.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted label-recommended prescriber/patient management actions that accompany the boxed warning (risk assessment, education, storage/disposal instructions, and frequent monitoring).
Suggested Improvement
Include the boxed warning’s accompanying actions (assess risk before prescribing, educate patients/families about abuse/misuse risk and proper storage/disposal, reassess risk throughout treatment, and frequently monitor for signs/symptoms of abuse/misuse/addiction) when summarizing the boxed warning.